Company Announcement no. 25/2012
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 18 December, 2012
Major shareholder announcement
Pursuant to section 29 of the Danish Securities Trading Act, Veloxis Pharmaceuticals A/S (OMX: VELO) hereby makes public, that the company has been informed that Alta Partners (including the funds affiliated thereto, being Alta BioPharma Partners III, L.P., Alta BioPharma Partners III, GmbH & Co. Beteiligungs KG, and Alta Embarcadero BioPharma Partners III, LLC) One Embarcadero Center, Suite 3700 San Francisco, CA 94111, United States, now holds less than 5% of the share capital and the voting rights in Veloxis Pharmaceuticals A/S.
Number of shares held by Alta Partners:
Alta BioPharma Partners III, L.P 25,988,848 shares
Alta BioPharma Partners III, GmbH & Co. Beteiligungs KG 1,745,432 shares
Alta Embarcadero BioPharma Partners III, LLC 640,440 shares
28,374,720 shares
Alta Partners consequently, directly and indirectly, holds 28,374,720 shares in Veloxis Pharmaceuticals A/S with a nominal value of DKK 0.1 each, equivalent to 1.71 % of the share capital and the voting rights.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
For further information, please visit www.veloxis.com.
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company’s lead product candidate is LCP‐Tacro for immunosuppression, specifically organ transplantation. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low‐scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
